Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Everolimus
Drug ID BADD_D00858
Description Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Indications and Usage Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Marketing Status approved
ATC Code L01EG02; L04AA18
DrugBank ID DB01590
KEGG ID D02714
MeSH ID D000068338
PubChem ID 6442177
TTD Drug ID D0K3QS
NDC Product Code 52076-6247; 62227-019; 68254-6234; 71052-559; 49884-283; 0054-0480; 0078-0566; 0078-0620; 0078-0627; 0378-3096; 0378-3097; 67877-721; 0054-0472; 70377-012; 65129-1324; 71796-012; 0078-0422; 0093-7767; 0093-7768; 49884-119; 51991-821; 63850-0062; 63850-0064; 70377-010; 70377-011; 63850-0059; 67877-718; 0054-0470; 17404-1027; 65727-064; 0078-0567; 51991-824; 63850-0058; 0378-0007; 0378-3098; 0054-0497; 65727-063; 0078-0594; 0078-0628; 49884-158; 0378-0005; 0378-3099; 67877-720; 0054-0471; 52076-6253; 62227-013; 70225-1103; 0078-0415; 0078-0417; 0078-0626; 0054-0482; 52076-6234; 63850-0063; 67877-719; 63850-0061; 0054-0481; 0054-0604; 49884-160; 51991-822; 63850-0060; 0378-0006; 70377-013; 65727-046; 0078-0414; 0093-7766; 49884-125; 49884-127; 49884-128; 49884-159; 51991-823
UNII 9HW64Q8G6G
Synonyms Everolimus | SDZ RAD | RAD, SDZ | SDZ-RAD | 40-O-(2-hydroxyethyl)-rapamycin | RAD 001 | 001, RAD | RAD001 | Certican | Afinitor
Chemical Information
Molecular Formula C53H83NO14
CAS Registry Number 159351-69-6
SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O) C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metastases to meninges17.02.10.012; 16.22.02.0030.000229%Not Available
Neuroendocrine tumour16.24.01.009; 05.08.01.0130.002905%Not Available
Palatal disorder07.05.01.0190.000336%Not Available
Small intestinal haemorrhage24.07.02.019; 07.12.03.0020.000229%
Lymphangiosis carcinomatosa24.09.02.007; 16.22.02.009; 01.09.01.0270.000535%Not Available
Small intestine carcinoma16.13.13.002; 07.21.01.0160.000153%Not Available
Breast cancer metastatic16.10.01.008; 21.05.01.0160.002553%Not Available
Hepatic mass09.01.08.0150.000459%Not Available
Biliary dilatation09.02.03.0040.000153%Not Available
Cell death14.11.02.005; 08.03.03.0030.000229%Not Available
Gastric varices haemorrhage09.01.06.014; 07.12.01.005; 24.07.02.0440.000153%Not Available
Hypertensive emergency24.08.01.0040.000229%Not Available
Communication disorder19.19.01.0080.000153%Not Available
Gastric mucosal lesion07.11.03.0070.000153%Not Available
Peritoneal disorder07.07.01.0100.000153%Not Available
Tricuspid valve disease02.07.05.0040.000153%
Angiodysplasia24.03.03.0170.000153%Not Available
Foaming at mouth07.05.05.019; 17.02.05.056; 08.01.03.0700.000596%Not Available
Nail bed inflammation23.02.05.0230.000153%Not Available
Rectal fissure07.03.01.0070.000153%
Pelvic fluid collection21.07.04.011; 07.07.01.0090.000153%Not Available
Astrocytoma, low grade17.18.04.001; 16.09.04.0010.000459%Not Available
Cerebral calcification17.11.01.0120.000489%Not Available
Apparent death08.01.03.0620.000229%Not Available
Pancreatic neuroendocrine tumour16.24.02.005; 07.21.09.009; 05.08.01.0140.002064%Not Available
Skin plaque23.03.03.0440.000382%Not Available
Oncologic complication16.32.03.0250.000917%Not Available
Pancreatic neuroendocrine tumour metastatic16.24.02.006; 07.21.09.010; 05.08.01.0150.000306%Not Available
Acute lung injury22.01.03.0100.000306%Not Available
Metastases to pelvis21.07.04.008; 16.22.02.0210.000382%Not Available
The 30th Page    First    Pre   30 31 32    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene